[Skip to Content]
[Skip to Content Landing]
January 3, 2007

Pexelizumab Does Not “Complement” Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Author Affiliations

Author Affiliations: Department of Medicine, McMaster University, Hamilton, Ontario.

JAMA. 2007;297(1):91-92. doi:10.1001/jama.297.1.91

Timely restoration of coronary artery blood flow using thrombolytic therapy, percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery salvages threatened myocardium and decreases cardiac morbidity and mortality. Reperfusion of ischemic tissues can, however, be associated with life-threatening reperfusion injury that can cause arrhythmias, myocardial stunning, microvascular dysfunction, and cell death.1 Accordingly, therapies that modulate reperfusion injury would be expected to enhance the effectiveness of thrombolysis and primary percutaneous coronary intervention for preserving myocardium and reducing mortality in patients with ST-elevation myocardial infarction (STEMI).